Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03231397 · ClinicalTrials.gov registry record · Phase 4
Predictors of AAA Expansion and/or Rupture
A Phase 4 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03231397 is a Phase 4 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 2 participants.
The verdict
NCT03231397, a Phase 4 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or because they do not have an AAA (control group). The purpose of this research study is to further study, through FEA, changes that occur in the mechanical properties of the aortic wall. The investigator will compare two radiotracers, 18F-FDG and 11C-PBR28 to determine if one provides more useful and reliable information about inflammation. 18F-FDG and 11C-PBR28 are radioactive drugs that will be used for imaging during the PET-CT scan. The investigator will also compare the results describing the mechanical properties of the AAA wall to the degree of inflammation in that wall as determined by PET-CT imaging to define new and better predictors of AAA growth and/or rupture.
Interventions
- DRUG Assess AAA rupture risk by PET-CTA scans
- DRUG 18F-fludeoxyglucose (FDG)
- DIAGNOSTIC_TEST 11C-PBR28
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03231397
The ClinicalTrials.gov registry entry for NCT03231397 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Assess AAA rupture risk by PET-CTA scans is the first listed.
NCT03231397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03231397 about?
NCT03231397 is a clinical study titled "Predictors of AAA Expansion and/or Rupture". Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or because they do not have an AAA (control group). The purpose of this research study is to further study, through FEA, changes that occur in the mechanical properties of the aortic wall. The investigator will...
What is the current status of trial NCT03231397?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2017-08-01. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT03231397?
The interventions under investigation include: Assess AAA rupture risk by PET-CTA scans (DRUG), 18F-fludeoxyglucose (FDG) (DRUG), 11C-PBR28 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03231397?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.